Literature DB >> 28823372

Bilioenteric anastomotic stricture in patients with benign and malignant tumors: prevalence, risk factors and treatment.

Ji-Qiao Zhu1, Xian-Liang Li1, Jian-Tao Kou1, Hong-Meng Dong1, Huan-Ye Liu1, Chun Bai1, Jun Ma1, Qiang He2.   

Abstract

BACKGROUND: Stricture formation at the bilioenteric anastomosis is a rare but important postoperative complication. However, information on this complication is lacking in the literature. In the present study, we aimed to assess its prevalence and predictive factors, and report our experience in managing bilioenteric anastomotic strictures over a ten-year period.
METHODS: A total of 420 patients who had undergone bilioenteric anastomosis due to benign or malignant tumors between February 2001 and December 2011 were retrospectively reviewed. Univariate and multivariate modalities were used to identify predictive factors for anastomotic stricture occurrence. Furthermore, the treatment of anastomotic stricture was analyzed.
RESULTS: Twenty-one patients (5.0%) were diagnosed with bilioenteric anastomotic stricture. There were 12 males and 9 females with a mean age of 61.6 years. The median time after operation to anastomotic stricture was 13.6 months (range, 1 month to 5 years). Multivariate analysis identified that surgeon volume (≤30 cases) (odds ratio: -1.860; P=0.044) was associated with the anastomotic stricture while bile duct size (>6 mm) (odds ratio: 2.871; P=0.0002) had a negative association. Balloon dilation was performed in 18 patients, biliary stenting in 6 patients, and reoperation in 4 patients. Five patients died of tumor recurrence, and one of heart disease.
CONCLUSIONS: Bilioenteric anastomotic stricture is an uncommon complication that can be treated primarily by interventional procedures. Bilioenteric anastomosis may be performed by a surgeon in his earlier training period under the guidance of an experienced surgeon. Bile duct size >6 mm may play a protective role.
Copyright © 2017 The Editorial Board of Hepatobiliary & Pancreatic Diseases International. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  anastomotic stricture; bile duct size; bilioenteric anastomosis; surgeon volume

Mesh:

Year:  2017        PMID: 28823372     DOI: 10.1016/S1499-3872(17)60033-X

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  6 in total

1.  Magnetic Anastomosis for Biliojejunostomy: First Prospective Clinical Trial.

Authors:  Xue-Min Liu; Xiao-Peng Yan; Hong-Ke Zhang; Feng Ma; Yan-Guang Guo; Chao Fan; Shan-Pei Wang; Ai-Hua Shi; Bo Wang; Hao-Hua Wang; Jian-Hui Li; Xiao-Gang Zhang; Rongqian Wu; Xu-Feng Zhang; Yi Lv
Journal:  World J Surg       Date:  2018-12       Impact factor: 3.352

Review 2.  [Complication management after bile duct surgery].

Authors:  J Bednarsch; C Trauwein; U P Neumann; T F Ulmer
Journal:  Chirurg       Date:  2020-01       Impact factor: 0.955

3.  Laparoscopic pancreaticoduodenectomy for periampullary tumors: lessons learned from 500 consecutive patients in a single center.

Authors:  Ki Byung Song; Song Cheol Kim; Woohyung Lee; Dae Wook Hwang; Jae Hoon Lee; Jaewoo Kwon; Yejong Park; Seung Jae Lee; Guisuk Park
Journal:  Surg Endosc       Date:  2019-06-18       Impact factor: 4.584

4.  Taming the BEASt: Management of Biliary-Enteric Anastomotic Strictures.

Authors:  Calvin H Y Chan
Journal:  Dig Dis Sci       Date:  2019-12       Impact factor: 3.199

5.  Treatment of complex complications after choledochal cyst resection by multiple minimal invasive therapies: A case report.

Authors:  Hoa Viet Nguyen; Dang Hai Do; Hung Van Nguyen; Tuan Hong Vu; Quan Quy Hong; Chung Ta Vo; Trang Huyen Thi Dang; Ngoc Bich Nguyen; Dung Thanh Le; Phuong Ha Tran; Lan Thi Nguyen
Journal:  Int J Surg Case Rep       Date:  2020-07-11

6.  Leakage and Stenosis of the Hepaticojejunostomy Following Surgery for Perihilar Cholangiocarcinoma.

Authors:  Jan Bednarsch; Zoltan Czigany; Daniel Heise; Sven Arke Lang; Steven W M Olde Damink; Tom Luedde; Philipp Bruners; Tom Florian Ulmer; Ulf Peter Neumann
Journal:  J Clin Med       Date:  2020-05-08       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.